In addition, the combination of the nonspecific depalmitoylation inhibitor palmostatin B (Palm‐B) with gilteritinib (FLT3 inhibitor) also significantly suppressed FLT3‐ITD‐mediated signaling and leukemia progression [60], indicating that raising the level of palmitoylation might also bring beneficial effects in leukemia. This evidence concerns the gene FLT3 and leukemia.